Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru

Clinical Infectious Diseases

Volumn 40, Issue 10, 2005, Pages 1395-1403

  Miranda Verastegui C ^a,c   Llanos Cuentas, A ^c   Arevalo I ^a   Ward, B J ^b   Matlashewski, G ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; IMIQUIMOD; MEGLUMINE ANTIMONATE;

ADOLESCENT; ADULT; AGED; ARTICLE; ATAXIA; BURN; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EDEMA; ERYTHEMA; FEMALE; HUMAN; INFANT; MALE; NEUROTOXICITY; PAIN; PERU; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCAR FORMATION; SKIN DEFECT; SKIN LEISHMANIASIS; SKIN ULCER; TISSUE INJURY; TREATMENT FAILURE; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; AMINOQUINOLINES; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT; INJECTIONS, INTRAVENOUS; LEISHMANIASIS, CUTANEOUS; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PERU;

EID: 18244373947     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/429238     Document Type: Article

References (29)

1. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 2001; 95:239-43.
2. Desjeux P. Leishmaniasis: public health aspects and control. Clin Dermatol 1996; 14:417-23.
3. Herwaldt BL. Leishmaniasis. Lancet 1999; 354:1191-9.
4. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997; 24:684-703.
5. Pirsig W. Diseases of the nasal region on ceramics of the Moche-culture in ancient Peru. Rhinol Suppl 1989; 9:27-36.
6. Dujardin JC, Banuls AL, Llanos-Cuentas A, et al. Putative Leishmania hybrids in the Eastern Andean valley of Huanuco, Peru. Acta Trop 1995; 59:293-307.
7. Croft SL, Coombs GH. Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003; 19:502-8.
8. Lira R, Sundar S, Makharia A, et al. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 1999; 180:564-7.
9. Soto I, Toledo J, Gutierrez P, et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001; 33:E57-61.
10. Soto J, Arana BA, Toledo J, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004; 38:1266-72.
11. Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol 1998; 134:25-30.
12. Buates S, Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J Infect Dis 1999; 179:1485-94.
13. Buates S, Matlashewski G. Identification of genes induced by a macrophage activator, S-28463, using gene expression array analysis. Antimicrob Agents Chemother 2001; 45:1137-42.
14. Arevalo I, Ward B, Miller R, et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 2001; 33:1847-51.
15. Hemmi H, Kaisho T, Takeuchi O, et al. Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3:196-200.
16. Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 2003; 3:984-93.
17. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002; 2:845-58.
18. Davies CR, Llanos-Cuentas EA, Pyke SD, Dye C. Cutaneous leishmaniasis in the Peruvian Andes: an epidemiological study of infection and immunity. Epidemiol Infect 1995; 114:297-318.
19. Davies CR, Llanos-Cuentas EA, Sharp SJ, et al. Cutaneous leishmaniasis in the Peruvian Andes: factors associated with variability in clinical symptoms, response to treatment, and parasite isolation rate. Clin Infect Dis 1997; 25:302-10.
20. Arana M, Evans DA, Zolessi A, Cuentas AL, Arevalo J. Biochemical characterization of Leishmania (Viannia) braziliensis and Leishmania (Viannia) peruviana by isoenzyme electrophoresis. Trans R Soc Trop Med Hyg 1990; 84:526-9.
21. Laguna del Estal P, Calabrese S, Zabala JA, Martin T. Neurological toxicity from pentavalent antimonials during the treatment of visceral leishmaniasis. Med Clin (Barc) 1994; 102:276-7.
22. Testerman TL, Gerster JF, Imbertson LM, et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 1995; 58:365-72.
23. Murray HW, Oca MJ, Granger AM, Schreiber RD. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J Clin Invest 1989; 83:1253-7.
24. Wagner TL, Ahonen CL, Couture AM, et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 1999; 191:10-9.
25. Seeberger J, Daoud S, Pammer J. Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod. Int J Dermatol 2003; 42: 576-9.
26. Asilian A, Jalayer T, Nilforooshzadeh M, et al. Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran. Bull World Health Organ 2003; 81:353-9.
27. Berman B, Kaufman J. Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol 2002; 47:S209-11.
28. Berman B, Villa A. Imiquimod 5% cream for keloid management. Dermatol Surg 2003; 29:1050-1.
29. Mahboudi F, Abolhassani M, Tehrani SR, Azimi M, Asmar M. Differentiation of old and new world L eishmania species at complex and species levels by PCR. Scand J Infect Dis 2002; 34:756-8.